BeyondSpring Inc. Restricted Cash and Cash Equivalents
BeyondSpring Inc. (BYSI) had Restricted Cash and Cash Equivalents of $0 as of 2024-12-31, per its 10-K filed 2025-03-27.
Financial Statements › Balance Sheet › Assets
us-gaap:RestrictedCashAndCashEquivalents · last filed 2025-03-27
- 2024-12-31: Restricted Cash and Cash Equivalents $0.00.
- 2023-12-31: Restricted Cash and Cash Equivalents $9.94M.
| Period end | Restricted Cash and Cash Equivalents |
|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-03-27 |
| 2023-12-31 | $9.94M 10-K · filed 2025-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |